ITC VerifyNow System Platelet Reactivity Test - Manual (Page 86)

Appendix - 11
Page 82 14439.C 03/2013 VerifyNow System User Manual | USA
Term Description
PAR-4 receptor
PAR-4 is one of four protease-activated receptors (PAR) located on the surface of
platelets. Thrombin activates PAR-4 by cleavage of part of its extracellular domain.
PAR-4 activating peptide (PAR-4 AP), a synthetic peptide, serves as a surrogate
for thrombin and activates the platelet through the PAR-4 receptor in the VerifyNow
PRUTest.
PAR-4 activating
peptide
PAR-4 activating peptide (PAR-4 AP), a synthetic peptide, serves as a surrogate
for thrombin and activates the platelet through the PAR-4 receptor in the VerifyNow
PRUTest.
Password
When operator identification is enabled, a user identification number and a
matching password number are required to use the instrument.
Patient
Identification
A feature that assigns a patient identification (ID) to each patient sample.
PAU See platelet aggregation units.
Pellet
A hygroscopic substance provided in the WQC kit and used in Level 2 wet quality
control testing. The active ingredient is a peptide that gives results that mimic
platelet function in an uninhibited sample.
Percent
inhibition
Percent inhibition (%) is the percent change from baseline aggregation, and is
calculated from a result and a baseline result (for IIb/IIIa Test only).
PGE1
The VerifyNow PRUTest uses PGE1 to increase intraplatelet cAMP and reduce the
contribution of the P2Y1 receptor on activation. This makes the test more specific
for the effects of ADP on the P2Y12 receptor.
Platelet
Also called a thrombocyte. A discoid cell found in large numbers in blood,
responsible for aggregation and contributing to haemostasis by repairing vascular
wall injuries.
Platelet
activation
Platelet activation induces a conformational change in the platelet glycoprotein IIb/
IIIa receptors on the surface of platelets to an activated high-affinity binding site for
fibrinogen and vWF. The platelet changes from a disc shape to a round shape with
long, filopodial extensions that can bind to adhesive proteins in circulation, such as
fibrinogen, to form a meshwork of platelets.
Platelet
aggregation
units
The IIb/IIIa test reports patient results in Platelet Aggregation Units (PAU). PAU is
calculated as a function of the rate and extent of aggregation.
Platelet function
test
A laboratory or point-of-care test to measure platelet activity or platelet inhibition
in patients. One method detects platelet activity by measuring in vitro platelet
aggregation in a blood sample exposed to specific agonists.
Platelet
inhibition
The condition in which or the process by which platelet aggregation is inhibited.
Platelet inhibition may be induced in response to a potent anti-platelet agent (e.g.
acetylsalicylic acid (aspirin), P2Y12 inhibitors, and GP IIb/IIIa inhibitors).
Plavix
Clopidogrel (trade name Plavix ® - clopidogrel bisulfate) is a potent oral antiplatelet
agent used in the treatment of coronary artery disease, peripheral vascular
disease, and cerebrovascular disease. As a thienopyridine, its mechanism of
action is inhibition of the P2Y12 receptor.
Prasugrel
Prasugrel (trade name Effient) is a novel antiplatelet agent used in the treatment
of patients with acute coronary syndromes. As a thienopyridine, its mechanism of
action is inhibition of the P2Y12 receptor.